Biogen admits Aduhelm launch ‘slower than we anticipated’

Biogen CEO Michel Vounatsos admitted Thursday that the launch of Aduhelm, the company’s intensely scrutinized treatment for Alzheimer’s disease, has been “slower than we anticipated,” which he blamed in part on “confusion, misinformation, and controversy” about whether the drug works and how it was approved.